A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Locally Advanced or|Metastatic Breast Cancer
Interventions: DRUG: Fulvestrant
Sponsor: AstraZeneca